3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Status
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gynecologic
3
Conditions
Ovarian Neoplasms
323
Fallopian Tube Neoplasms
159
Carcinoma, Ovarian Epithelial
114
Endometrial Neoplasms
77
Uterine Cervical Neoplasms
72
Neoplasms
28
Carcinoma, Non-Small-Cell Lung
24
Breast Neoplasms
23
Brenner Tumor
21
Recurrence
19
Testicular Neoplasms
17
Peritoneal Neoplasms
17
Stomach Neoplasms
14
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
11
Urinary Bladder Neoplasms
10
Testicular Germ Cell Tumor
10
Sarcoma
10
Pancreatic Neoplasms
10
Lung Neoplasms
10
Colorectal Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
9
Teratoma
8
Ovarian Germ Cell Cancer
8
Neuroectodermal Tumors, Primitive, Peripheral
8
Central Nervous System Neoplasms
8
Uterine Neoplasms
7
Small Cell Lung Carcinoma
7
Melanoma
7
Interventions
Paclitaxel
4
liposomal doxorubicin
3
Carboplatin
3
pembrolizumab
2
Bevacizumab
2
1-dodecylpyridoxal
2
poly(I).poly(c12,U)
1
mirabegron
1
disitamab vedotin
1
apatinib
1
anlotinib
1
Tocotrienols
1
Platinum Compounds
1
Lenalidomide
1
Interferon alpha-2
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gemcitabine
1
EP-100 membrane-disrupting peptide
1
Cisplatin
1
AC 7700
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Ovarian Cancer Recurrent
×
Carboplatin
×
Gynecologic
×
Clear all
NCT06843447
2026-05-26
MK-5909-003
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
460 enrolled
NCT04072263
2021-04-01
OVACURE
Leiden University Medical Center
Phase 1/2
Unknown
12 enrolled
NCT01332656
2015-12-21
OPSALIN
Sanofi
Phase 2
Completed
154 enrolled